• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结膜下注射贝伐单抗辅助难治性青光眼小梁切除术:病例系列

Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: a case series.

作者信息

Choi Jin Young, Choi Jaewan, Kim Yeon-Deok

机构信息

HanGil Eye Hospital, Incheon, Korea.

出版信息

Korean J Ophthalmol. 2010 Feb;24(1):47-52. doi: 10.3341/kjo.2010.24.1.47. Epub 2010 Feb 5.

DOI:10.3341/kjo.2010.24.1.47
PMID:20157415
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2817825/
Abstract

This prospective observational case series study included 6 eyes of 6 consecutive glaucomatous patients. Each patient underwent trabeculectomy with mitomycin C, and received a 1.25 mg of subconjunctival bevacizumab injection at completion of the trabeculectomy. Study eyes included two with neovascular glaucoma, three with uveitic glaucoma, and one with secondary glaucoma following vitrectomy. All eyes had undergone failed glaucoma laser/surgical treatment or an intraocular surgical procedure. Intraocular pressure (IOP) at the following postoperative visits: preoperative, 1 week, 1 month, 2 months, 3 months, and 6 months, was measured. We also evaluated postoperative bleb findings and complications. IOP measured at each visit was 37.5+/-14.4 mmHg, 6.2+/-3.4 mmHg, 8.3+/-7.2 mmHg, 12.0+/-4.4 mmHg, 10.8+/-3.1 mmHg, and 12.2+/-3.3 mmHg, respectively, for each visit. All eyes had functioning blebs with normal IOP at postoperative 6 months with no additional IOP-lowering medication.

摘要

这项前瞻性观察性病例系列研究纳入了6例连续的青光眼患者的6只眼睛。每位患者均接受了丝裂霉素C小梁切除术,并在小梁切除术完成时结膜下注射1.25 mg贝伐单抗。研究眼包括2例新生血管性青光眼、3例葡萄膜炎性青光眼和1例玻璃体切除术后继发性青光眼。所有眼睛均曾接受青光眼激光/手术治疗失败或眼内手术。测量术后随访时(术前、1周、1个月、2个月、3个月和6个月)的眼压。我们还评估了术后滤过泡情况和并发症。每次随访时测量的眼压分别为37.5±14.4 mmHg、6.2±3.4 mmHg、8.3±7.2 mmHg、12.0±4.4 mmHg、10.8±3.1 mmHg和12.2±3.3 mmHg。所有眼睛在术后6个月时滤过泡功能良好,眼压正常,无需额外的降眼压药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8af4/2817825/0bdbdb1c49f3/kjo-24-47-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8af4/2817825/c2cc6f193ae3/kjo-24-47-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8af4/2817825/0bdbdb1c49f3/kjo-24-47-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8af4/2817825/c2cc6f193ae3/kjo-24-47-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8af4/2817825/0bdbdb1c49f3/kjo-24-47-g002.jpg

相似文献

1
Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: a case series.结膜下注射贝伐单抗辅助难治性青光眼小梁切除术:病例系列
Korean J Ophthalmol. 2010 Feb;24(1):47-52. doi: 10.3341/kjo.2010.24.1.47. Epub 2010 Feb 5.
2
Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.小梁切除术辅助结膜下注射贝伐单抗的评估:一项初步研究
Ophthalmology. 2008 Dec;115(12):2141-2145.e2. doi: 10.1016/j.ophtha.2008.06.009. Epub 2008 Aug 9.
3
The outcome of initial mitomycin C-augmented trabeculectomy with subconjunctival bevacizumab in the management of secondary glaucoma associated with Fuchs heterochromic iridocyclitis.初始丝裂霉素 C 增强小梁切除术联合结膜下贝伐单抗治疗与 Fuchs 异色性虹膜睫状体炎相关的继发性青光眼的疗效。
Int Ophthalmol. 2020 Apr;40(4):795-802. doi: 10.1007/s10792-019-01240-3. Epub 2019 Dec 3.
4
Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.抗血管内皮生长因子药物玻璃体腔内注射联合保守滤过手术治疗新生血管性青光眼的疗效观察。
J Glaucoma. 2010 Mar;19(3):212-8. doi: 10.1097/IJG.0b013e3181aae928.
5
Needle bleb revision with bevacizumab and mitomycin C compared with mitomycin C alone for failing filtration blebs.与单独使用丝裂霉素C相比,贝伐单抗联合丝裂霉素C用于失败滤过泡的针吸泡修复。
J Glaucoma. 2015 Apr-May;24(4):311-5. doi: 10.1097/IJG.0b013e31829f9bd3.
6
The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma.不同剂量前房内注射贝伐单抗对新生血管性青光眼小梁切除术手术效果的影响
Eur J Ophthalmol. 2009 May-Jun;19(3):435-41. doi: 10.1177/112067210901900318.
7
Comparison of needle revision with subconjunctival bevacizumab and 5-fluorouracil injection of failed trabeculectomy blebs.比较失败的小梁切除术后滤过泡针拨术与结膜下贝伐单抗和 5-氟尿嘧啶注射。
J Ocul Pharmacol Ther. 2012 Oct;28(5):542-6. doi: 10.1089/jop.2012.0035. Epub 2012 Jun 25.
8
Role of subconjunctival bevacizumab as an adjuvant to primary trabeculectomy: a prospective randomized comparative 1-year follow-up study.结膜下注射贝伐单抗作为原发性小梁切除术辅助治疗的作用:一项前瞻性随机对照1年随访研究。
J Glaucoma. 2015 Jan;24(1):1-8. doi: 10.1097/IJG.0b013e318287abf3.
9
Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma.玻璃体内联合应用贝伐单抗和小梁切除术联合丝裂霉素 C 与单独小梁切除术联合丝裂霉素 C 治疗新生血管性青光眼。
J Glaucoma. 2011 Mar;20(3):196-201. doi: 10.1097/IJG.0b013e3181d9ce12.
10
Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.玻璃体内注射贝伐单抗与滤过手术治疗新生血管性青光眼的手术结果
Adv Ther. 2008 May;25(5):438-43. doi: 10.1007/s12325-008-0047-5.

引用本文的文献

1
Efficacy of anti-vascular endothelial growth factor and mitomycin C on wound healing after trabeculectomy in glaucoma patients: A meta-analysis.抗血管内皮生长因子和丝裂霉素 C 对青光眼患者小梁切除术后伤口愈合的疗效:Meta 分析。
Int Wound J. 2024 Apr;21(4):e14517. doi: 10.1111/iwj.14517. Epub 2023 Dec 13.
2
Short-Term Results of Sutureless Scleral Tunnel Trabeculectomy Using Adjunctive Topical Bevacizumab.使用辅助性局部注射贝伐单抗的无缝合巩膜隧道小梁切除术的短期结果
Med Hypothesis Discov Innov Ophthalmol. 2018 Summer;7(2):63-67.
3
Suppression of Human Tenon Fibroblast Cell Proliferation by Lentivirus-Mediated VEGF Small Hairpin RNA.

本文引用的文献

1
Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery.抑制血管内皮生长因子可减少青光眼滤过术后瘢痕形成。
Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5217-25. doi: 10.1167/iovs.08-2662. Epub 2009 May 27.
2
Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit.贝伐单抗在兔青光眼滤过手术中作为抗纤维化药物的术后应用。
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3233-7. doi: 10.1167/iovs.08-2441. Epub 2009 Jan 31.
3
Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.
慢病毒介导的VEGF小发夹RNA对人Tenon成纤维细胞增殖的抑制作用
J Ophthalmol. 2017;2017:7982051. doi: 10.1155/2017/7982051. Epub 2017 Jan 11.
4
Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery.抗血管内皮生长因子用于控制青光眼手术中的伤口愈合
Cochrane Database Syst Rev. 2016 Jan 15;2016(1):CD009782. doi: 10.1002/14651858.CD009782.pub2.
5
Neovascular Glaucoma.新生血管性青光眼
Dev Ophthalmol. 2016;55:196-204. doi: 10.1159/000431196. Epub 2015 Oct 26.
6
Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma.评估贝伐单抗与丝裂霉素联合用于小梁切除术治疗复发性儿童青光眼的辅助作用。
Eye (Lond). 2016 Jan;30(1):53-8. doi: 10.1038/eye.2015.182. Epub 2015 Oct 2.
7
The efficiency of subconjunctival bevacizumab in refractory glaucoma - case report.结膜下注射贝伐单抗治疗难治性青光眼的疗效——病例报告
J Med Life. 2015 Jan-Mar;8(1):103-5.
8
Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study.小梁切除术后局部应用贝伐单抗预防滤过泡失败:一项初步研究。
J Ocul Biol Dis Infor. 2013 Jun 27;5(3-4):89-95. doi: 10.1007/s12177-013-9108-3. eCollection 2012 Dec.
9
Anti-VEGF Agents and Glaucoma Filtering Surgery.抗血管内皮生长因子药物与青光眼滤过手术
J Ophthalmic Vis Res. 2013 Apr;8(2):182-6.
10
Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma.低剂量结膜下注射贝伐单抗辅助小梁切除术治疗青光眼。
Clin Ophthalmol. 2011;5:797-800. doi: 10.2147/OPTH.S17896. Epub 2011 Jun 15.
小梁切除术辅助结膜下注射贝伐单抗的评估:一项初步研究
Ophthalmology. 2008 Dec;115(12):2141-2145.e2. doi: 10.1016/j.ophtha.2008.06.009. Epub 2008 Aug 9.
4
Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.玻璃体内注射贝伐单抗治疗41例连续性缺血性视网膜疾病继发的虹膜新生血管和新生血管性青光眼。
Ophthalmology. 2008 Sep;115(9):1571-80, 1580.e1-3. doi: 10.1016/j.ophtha.2008.02.026. Epub 2008 Apr 28.
5
The effect of topical bevacizumab on corneal neovascularization.局部应用贝伐单抗对角膜新生血管形成的影响。
Ophthalmology. 2008 Jun;115(6):e33-8. doi: 10.1016/j.ophtha.2008.02.013. Epub 2008 Apr 24.
6
Regulation of scar formation by vascular endothelial growth factor.血管内皮生长因子对瘢痕形成的调控
Lab Invest. 2008 Jun;88(6):579-90. doi: 10.1038/labinvest.2008.36. Epub 2008 Apr 21.
7
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.贝伐单抗作为炎症性角膜血管生成和淋巴管生成的强效抑制剂。
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2545-52. doi: 10.1167/iovs.06-0570.
8
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.抑制血小板衍生生长因子(PDGF)、血管内皮生长因子(VEGF)和成纤维细胞生长因子(FGF)信号传导可减轻纤维化。
Eur Respir J. 2007 May;29(5):976-85. doi: 10.1183/09031936.00152106. Epub 2007 Feb 14.
9
Intravitreal bevacizumab for filtering surgery.玻璃体内注射贝伐单抗用于滤过性手术。
Ophthalmic Res. 2007;39(2):121-2. doi: 10.1159/000099248. Epub 2007 Feb 2.
10
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).贝伐单抗(阿瓦斯汀)对实验性角膜新生血管形成的抑制作用
Br J Ophthalmol. 2007 Jun;91(6):804-7. doi: 10.1136/bjo.2006.107912. Epub 2006 Dec 19.